January 25, 2006


A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


ZOLL Medical Announces Technology Agreement with Novation for AutoPulse 

Thursday, January 26, 2006 – CHELMSFORD, MASS. - ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it signed a three-year contract with Novation, the health care contracting services company of VHA Inc. and University HealthSystem Consortium (UHC) that serves the purchasing needs of more than 2,500 VHA Inc. and UHC members. The agreement covers the ZOLL AutoPulse® Non-invasive Cardiac Support Pump, and offers an opportunity for ZOLL’s direct sales force to bring additional value to Novation’s members.

ZOLL has had a relationship with Novation that dates back to 1999, based on positive performance reviews by Novation and member councils. The new agreement was reached after Novation’s Nursing and Clinical Practice Council reviewed the AutoPulse using its new technology evaluation process. The Council found, after careful review of the product and supporting documentation, that the AutoPulse was unique and proprietary in the market and offered incremental patient benefits.

“The AutoPulse has gained significant credibility in the hospital marketplace as a result of this agreement,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “The agreement is another proof point that the AutoPulse will advance the practice of resuscitation among medical professionals.”

Approximately 235 EMS agencies and hospitals worldwide employ the AutoPulse. A number of member hospitals currently use the AutoPulse as part of their resuscitation efforts, including the University of North Carolina (UNC) Medical Center, the Medical College of Virginia Hospitals, Stanford Medical Center in California, and Nebraska Medical Center.

The AutoPulse is an automated, portable device comprised of a backboard and a simple, load-distributing LifeBand® that fastens across a victim’s chest. The AutoPulse compresses the entire chest, in a unique, consistent “hands-free” manner, delivering maximum blood flow to the heart and brain* without interruption or fatigue. Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions.

About Novation

Based in Irving, Texas, Novation was established in January 1998 through a combination of the supply programs of VHA and UHC, two national health care alliances. Novation serves the purchasing needs of more than 2,500 members and affiliates of VHA and UHC. These organizations used Novation contracts to purchase more than $23 billion in supplies in 2004.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East, Asia, and Australia. For more information, visit www.zoll.com or call +1 (978) 421-9655.

Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the hospital business; acceptance of the AutoPulse; changes in regulations affecting the healthcare industry; general economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Annual Report on Form 10-K, which was filed with the SEC on December 15, 2005.

© 2006 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, LifeBand, and ZOLL are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.

*Clinical data available upon request.